---
title: "Compugen Q2 FY26 net loss narrows to USD 7 million; revenue more than doubled to USD 2.6 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294682854.md"
description: "Compugen reported a narrowed Q2 FY26 GAAP net loss of USD 7.01 million, down from USD 7.34 million year-over-year. Revenue more than doubled to USD 2.6 million, driven by Gilead milestone payments. R&D and G&A expenses increased slightly. The company holds USD 125.3 million in cash, funding operations into 2029. MAIA-ovarian interim analysis for COM701 is on track, with median PFS data expected by Q1 2027."
datetime: "2026-08-03T11:04:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294682854.md)
  - [en](https://longbridge.com/en/news/294682854.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294682854.md)
generator: "portal-rs"
---

# Compugen Q2 FY26 net loss narrows to USD 7 million; revenue more than doubled to USD 2.6 million

-   Compugen posted a Q2 GAAP net loss of USD 7.01 million, narrowing from USD 7.34 million a year earlier. \* Revenue more than doubled to USD 2.6 million, reflecting recognition of Gilead upfront and IND milestone payments. \* R&D expenses rose 11.8% to USD 6.31 million, while G&A spending edged up to USD 2.26 million. \* Cash and cash-related balances totaled about USD 125.3 million at June 30, with runway expected to fund operations into 2029. \* MAIA-ovarian interim analysis for COM701 remains on track, with median progression-free survival data expected by Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608030700PR\_NEWS\_USPR\_\_\_\_\_LN17303) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CGEN.US](https://longbridge.com/en/quote/CGEN.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [New HIV and Breast Cancer Wins Might Change The Case For Investing In Gilead Sciences (GILD)](https://longbridge.com/en/news/297483843.md)
- [FDA Approves Gilead's New Single Tablet HIV Regimen](https://longbridge.com/en/news/297549407.md)
- [Bamco Inc. NY Sells 12,000 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/297281302.md)
- [MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Buys 46,620 Shares](https://longbridge.com/en/news/297763003.md)
- [Parallax Volatility Advisers L.P. Trims Holdings in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/297162579.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**